Detection and treatment of subclinical tuberculosis.

Reduction of active disease by preventive therapy has the potential to make an important contribution towards the goal of tuberculosis (TB) elimination. This report summarises discussions amongst a Working Group convened to consider areas of research that will be important in optimising the design and delivery of preventative therapies. The Working Group met in Cape Town on 26th February 2012, following presentation of results from the GC11 Grand Challenges in Global Health project to discover drugs for latent TB.

[1]  Sang-Nae Cho,et al.  Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. , 2010, Chest.

[2]  Yang Liu,et al.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages , 2003, The Journal of experimental medicine.

[3]  JoAnne L. Flynn,et al.  Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque Model , 2009, Infection and Immunity.

[4]  Peter Gwynne,et al.  Drug Discovery: 5 , 2002 .

[5]  John P. Ray,et al.  Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections , 2012, Cell.

[6]  C. Senner,et al.  Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.

[7]  W. Hanekom,et al.  The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. , 2012, American journal of respiratory and critical care medicine.

[8]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[9]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[10]  K. Kupferschmidt.  Infectious disease. Taking a new shot at a TB vaccine. , 2011, Science.

[11]  K. Andries,et al.  Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[12]  T. Ottenhoff,et al.  High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening , 2011, Thorax.

[13]  E. Rubin,et al.  Characterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters , 2011, mBio.

[14]  G. Kaplan,et al.  Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs , 2011, PLoS pathogens.

[15]  Jacques Neefjes,et al.  Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 , 2007, Nature.

[16]  R. Hayes,et al.  Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial , 2010, The Lancet.

[17]  Thomas Dick,et al.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.

[18]  C. Dye,et al.  The Population Dynamics and Control of Tuberculosis , 2010, Science.

[19]  C. Sismanidis,et al.  Prevalence of Tuberculosis, HIV and Respiratory Symptoms in Two Zambian Communities: Implications for Tuberculosis Control in the Era of HIV , 2009, PloS one.

[20]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[21]  J. Stark,et al.  Systems biology of persistent infection: tuberculosis as a case study , 2008, Nature Reviews Microbiology.

[22]  B. Vickery,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2011, Pediatrics.

[23]  J. Hackman,et al.  Three months of rifapentine and isoniazid for latent tuberculosis infection. , 2011, The New England journal of medicine.

[24]  Martin Meier-Schellersheim,et al.  Systems biology in immunology: a computational modeling perspective. , 2011, Annual review of immunology.

[25]  G. Maartens,et al.  Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. , 2009, American journal of respiratory and critical care medicine.

[26]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[27]  R. Wilkinson,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. , 2009, Clinics in chest medicine.

[28]  S. Kaufmann,et al.  Mycobacterium tuberculosis: success through dormancy. , 2012, FEMS microbiology reviews.

[29]  F. Cobelens,et al.  National survey of tuberculosis prevalence in Viet Nam. , 2010, Bulletin of the World Health Organization.

[30]  T. Dick,et al.  How antibacterials really work: impact on drug discovery. , 2011, Future microbiology.

[31]  Ying Zhang,et al.  Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis , 2011, Science.

[32]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[33]  Stefan H E Kaufmann,et al.  Future vaccination strategies against tuberculosis: thinking outside the box. , 2010, Immunity.

[34]  M. Pai,et al.  What Research Is Needed to Stop TB? Introducing the TB Research Movement , 2011, PLoS medicine.

[35]  D Repsilber,et al.  Human gene expression profiles of susceptibility and resistance in tuberculosis , 2011, Genes and Immunity.

[36]  A. Harries,et al.  Interim policy on collaborative TB / HIV activities. , 2004 .